BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine
Maria Panagopoulou, Theodoros Panou, Anastasios Gkountakos, Gesthimani Tarapatzi, Makrina Karaglani, Ioannis Tsamardinos, Ekaterini Chatzaki · 2024
Read BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine by Maria Panagopoulou, Theodoros Panou, Anastasios Gkountakos, Gesthimani Tarapatzi, Makrina Karaglani, Ioannis Tsamardinos, Ekaterini Chatzaki (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11622545.txt.
Description
Maria Panagopoulou and co-workers review methylation of the BRCA1 and BRCA2 genes as a cancer biomarker, in a 2024 paper. These genes repair broken DNA, and tumors that lose that repair skill respond to a class of drugs called PARP inhibitors. Methylation can switch the genes off without any mutation.
That switched-off state, often called BRCAness, links to cancer development and poor outlook, mainly in breast and ovarian cancer. The review covers how methylation arises, what tumors with it look like, and whether testing blood samples for it can predict drug response. The authors say clinical use is promising but still under-evaluated.
Catalog record
| CREATOR | Maria Panagopoulou, Theodoros Panou, Anastasios Gkountakos, Gesthimani Tarapatzi, Makrina Karaglani, Ioannis Tsamardinos, Ekaterini Chatzaki |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |